

**DKMSx**  
WE DELETE BLOOD CANCER

# UK Impact Report



Year ending 31 December 2024

Tasneem, DKMS volunteer (East  
Midlands) and valued DKMS supporter



## Our Vision

To delete blood cancer.

---



## Our Mission

To give as many blood cancer patients as possible a second chance at life.

---



## Our Purpose

To raise awareness of blood cancer and blood disorders, register and retain potential stem cell donors to provide a second chance at life, raise funds to match donor registration costs, provide access to transplantation for more blood cancer patients, and improve blood cancer therapies by our own research.

# Contents

Managing Directors' introduction	02
Surpassing donor registration	03
Representation matters	05
From frontline to lifeline	07
From grief to giving	09
Giving back through fundraising	11
DKMS UK support to India & Access to Transplantation	13
Trustee report	15
Statement of financial activities	27
Ways you can support us	51

# Managing Directors' *introduction*

We warmly welcome and thank you for your engagement with and support for DKMS UK. We look back on an eventful year 2024 and to review all that was achieved is truly humbling.

We supported many wonderful initiatives for and with our patients and supporters, registering **more than 50,000 potential lifesavers**. Our new e-registration application simplifies the process of registering as a stem cell donor while enhancing the data quality.

Our fundraising efforts focused on forging long-term, mutually beneficial partnerships and we tried something totally new: we launched the DKMS Lottery, which exceeded all our expectations. The Marketing and Communications team prioritised brand awareness, as we recognised that to be truly successful, the foundation from which we must grow is ensuring the people of the UK know who we are, what we stand for and what our life-saving mission is.

2024 was also a significant year for our medical departments: we expanded our staff to provide an even **better and faster service to patients' transplant centre teams** and our donors in 2025. DKMS UK also achieved World Marrow Donor Association (WMDA) accreditation, demonstrating our commitment to upholding the highest standards.

Fair and equitable access to stem cell transplantation is a focus for DKMS globally. In the UK, minority ethnic representation stands at 16%. This is simply not good enough and we are focused on significantly increasing activities within underrepresented communities to sign up more donors in 2025 and beyond. In 2024, DKMS UK extended its influence beyond national borders, supporting our organisation's work in India. Additionally, DKMS' global Access to Transplantation Programme offers patients in low-income countries access to treatment for blood cancer, thalassaemia, and sickle cell disease, which you can read about in this report.

**We achieved so much in 2024, and yet there is so much more to do in 2025 and beyond.** We are confident that the foundations we have laid this past year will, with your help, enable us to support even more blood cancer patients through our collective essential work.



**Peter McCleave**



**Hasnein Alidina**

---





Surpassing  
donor registration



Representation  
matters



From frontline  
to lifeline



From grief  
to giving



Giving back  
through fundraising



DKMS UK  
support

# 01

## Surpassing donor *registration*

When Tracy, a 34-year-old mother of two, was diagnosed with acute myeloid leukaemia (AML), she had four rounds of chemotherapy. After her fourth round, she relapsed and was told that she needed more chemotherapy and a stem cell transplant, her only chance for complete remission.

Tracy's community in Omagh, Northern Ireland rallied around her. Her family reached out to DKMS for help organising a stem cell donor registration drive.

---

**“Tracy didn’t have a 100% donor match,” explains her sister Louise. “So, we decided to make a public appeal locally, partnering with DKMS to encourage people to join the stem cell donor register.”**

---

Volunteers spread the word on social media, distributed materials to local businesses, PTAs, churches, and clubs, and shared the event via word of mouth in their tight-knit community. The registration event saw 600 registrations in the first four hours. So many came that a second drive was held. People queued around the block to join the stem cell register as potential donors, and DKMS flew in more swabs from England to make sure everyone could sign up.

This was DKMS UK's biggest registration event in recent years, thanks to the engagement of Tracy's community networks and the people of Omagh. Almost **1,500 people turned up** to support Tracy and patients like her, **1,336 people** made online kit requests and **£7,000 was raised**. Tracy's family were so moved to see the huge turnout and overwhelmed by the strength of their community.



---

**“We were absolutely  
overwhelmed by  
the support!”**

---

01

Surpassing  
donor registration

02

Representation  
matters

03

From frontline  
to lifeline

04

From grief  
to giving

05

Giving back  
through fundraising

06

DKMS UK  
support

## 02 Representation *matters*

The South Asian community is underrepresented on the stem cell donor register. This year, however, an unwavering commitment to encourage people to sign up – regardless of background or religion – was embodied by Tasneem, a Leicester-based mother, GP and dedicated advocate for stem cell donation.

Tasneem, a member of the DKMS East Midlands volunteering hub, has very personal reasons for supporting the work of DKMS: her own son Yusuf, now 16, was diagnosed with acute leukaemia five years ago. She recalls:

**“During the time my son was going through treatment, I sadly saw children with cancer who passed away after not being able to find a match. This seemed so unfair. Being of South Asian origin myself, I saw this as an opportunity to help.”**







As a Muslim woman from a South Asian background, as well as a GP, Tasneem is a trusted voice from her community.

She works to increase sign-ups to the stem cell donor register by helping to break down taboos and misunderstandings about stem cell donation.

Tasneem ran several events last year, including a donor registration drive in Highcross Shopping Centre, signing up **188 potential stem cell donors**. Tasneem was also instrumental in establishing a partnership between DKMS UK and Islamic Relief, a renowned charity working to improve lives across the Muslim community.

Tasneem's achievements remind us all that change begins with a single step — with every new person registered bringing hope to those searching for a compatible stem cell donor match.

01

Surpassing  
donor registration



02

Representation  
matters



03

From frontline  
to lifeline



04

From grief  
to giving



05

Giving back  
through fundraising



06

DKMS UK  
support



03

## From frontline to *lifeline*

Paul Smith, 57, from Bexley, has dedicated his life to service. He's a former firefighter who has donated blood 83 times and aims for 100. "I've always felt that donating is such an easy way to help others," he says. Paul joined the stem cell register over 20 years ago and is an advocate for donor registration, particularly within Black and other UK ethnic minority communities.


In January 2024, Paul found out he was a match. Despite initial concerns about his age, he went ahead with the donation, supported by his daughter.

---

**"DKMS were amazing at every stage, and post-donation when I was invited to join a special Facebook group for DKMS donors – I really valued that support being available," he adds.**

---





Paul's donation gave a young woman in the UK a second chance at life. "My children are very proud of me, and that often makes me get a bit teary when I think about it".

Paul's dedication goes beyond donating. During Blood Cancer Awareness Month in 2024, he teamed up with DKMS UK to speak at The Prince's Trust Youth Voice Programme's #Time2Inspire International Youth Day event. He connected with young people from the Black community, many of whom had never heard of stem cell donation. His powerful storytelling sparked curiosity and action. "It's really important for people in our community," one participant shared. "More awareness should be raised, and I'd like to learn more about it."

Paul's dedication continues to inspire and is a testament to the power of one person's actions.





01

Surpassing  
donor registration

02

Representation  
matters

03

From frontline  
to lifeline

04

From grief  
to giving

05

Giving back  
through fundraising

06

DKMS UK  
support

## 04

From grief to *giving*

Cecilia was a journalism student when her mother was diagnosed with diffuse large B-cell lymphoma. For over a year, she was by her mum's side through gruelling chemotherapy and treatments.

When doctors needed monocytes, Cecilia didn't hesitate; she underwent cell collection to help give her mum more time. Despite their best efforts, Cecilia's mum sadly passed away. But instead of letting grief define her, Cecilia transformed her pain into purpose.

For her final-year journalism project, Cecilia created Dear Cells, a documentary exploring cell therapy.

Through interviews with medical experts, charities including DKMS, and survivors, she set out to demystify stem cell donation and share its lifesaving potential.

Cecilia also registered as a stem cell donor and became a DKMS volunteer. From Freshers Fairs to patient-led drives and fundraising days, she brings warmth, empathy, and a powerful personal story.

Now leading her university's Stem Cell Society, a DKMS-affiliated volunteering group, Cecilia is committed to engaging students, staff, and local communities in



conversations about blood cancers, blood disorders, and the importance of joining the stem cell registry.

Cecilia's journey is a testament to the impact one person can make. She's not only keeping her mother's memory alive – she's helping save the lives of others.

---

**“I want to bring happiness to people, to see smiles on their faces, as I understand the hopelessness they and their families feel upon hearing a diagnosis,” she says.**

---





01

Surpassing  
donor registration



02

Representation  
matters



03

From frontline  
to lifeline



04

From grief  
to giving



05

Giving back  
through fundraising



06

DKMS UK  
support

05

## *Giving back* through fundraising



Matty from Newcastle was just 25 when he received the devastating diagnosis of Hodgkin lymphoma, an aggressive blood cancer.

Six years later, thanks to a selfless donor on the DKMS stem cell register, Matty is thriving.

---

**“It was a very tough challenge starting at 4am and finishing at 6pm. I ended up walking 50,000 steps that day! However, it was all worth it, as we raised £4,345 for DKMS, which was incredibly rewarding.”**

---



Motivated by his experience, Matty is determined to give back by fundraising to support DKMS's lifesaving mission.

"When a group of my friends and I decided to organise a charity golf tournament, we all agreed to support DKMS through this event, as the charity had helped find my matching stem cell donor. Everyone wanted to contribute because they knew how DKMS had helped save my life."

It costs DKMS £40 to register a potential donor to the stem cell register, meaning Matty and his friends raised enough to cover the cost of 108 potential lifesavers.

Matty's stem cell donor gave him a second chance at life; valuable time which he is using to help other patients find their perfect match. He's also embracing new challenges and appreciating everyday pleasures.

---

**"Since my transplant, I've competed in the World Transplant Games, winning two silver medals in slalom snowboarding in Banff, Canada, and I'm gearing up to compete again next year in Dresden, Germany. Being outside has been a huge part of my healing. Even the simple things, like taking my dog to the beach every day, I feel so grateful for."**

---



01

Surpassing  
donor registration

02

Representation  
matters

03

From frontline  
to lifeline

04

From grief  
to giving

05

Giving back  
through fundraising

06

DKMS UK  
support

06

# DKMS UK support to *India*

In 2024, DKMS UK played a vital role in strengthening India's efforts against blood cancer and other blood disorders through marketing and outreach.

These efforts resulted in over 55,000 online and in-person registrations, with a wider, positive impact on DKMS' goal of increasing the donor pool with more diverse HLA types.

Potential donors registered in India not only offer hope for their compatriots, but also worldwide

for people of similar heritages, including in the UK where ethnic minority communities are very underrepresented on the stem cell donor register.

DKMS' global Access to Transplantation programme, offering patients in low-income countries access to treatment for blood cancers and disorders, also plays an essential role, as we see in Jasper's story below.

## Jasper - Access to *Transplantation*

Mirror reporter Jeremy Armstrong met Jackson in Zambia, who told him that he had lost a son to sickle cell disease and now his 11-year-old, Jasper, also had it.

Jeremy connected them with DKMS UK. We facilitated free HLA typing and Jasper's sister Mercy was a perfect stem cell donor match. Because the potentially lifesaving procedure is unavailable in Zambia, Jeremy, The Mirror and DKMS' Access to Transplantation programme worked together to

fly Jasper, Mercy and their mother Carol to Bangalore, India, where Jasper had a stem cell transplant at the DKMS-funded BMJH-Sankalp Centre.

After ten months of care, Jasper was back home in time for Christmas and his twelfth birthday.

Jasper's story is a powerful reminder that access to healthcare should not depend on geography and the ability to access care.



# Our work in *pictures*



# DKMS Foundation: Trustee Report

## Preparation of report

The company qualifies as small under section 383 of the Companies Act 2006, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

DKMS Foundation (referred to hereinafter as 'DKMS UK') is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales, and in Scotland. It is governed by its Memorandum and Articles of Association. The activities, management, finances and strategy of the Charity are overseen by a Board of Trustees, who are also the Company Directors.

DKMS UK is connected through common Trustees to DKMS Group gGmbH ('DKMS'), and its related charities.

The Trustees who held office during the financial year and at the date of the report are set out on page 56.

A minimum of two Trustees at any one time are required by the Articles of Association. There is no maximum limit required by the Articles. At every Annual General Meeting (AGM) one-third of the Trustees retire by rotation and are eligible for re-election. There is no restriction on the term of tenure as a Trustee. Trustees do not receive remuneration for their duties.

## Purpose

DKMS UK's charitable purposes are set out in its Memorandum of Association as follows:

---

**“The preservation and protection of good health and the relief of sickness of individuals who are suffering from any kind of blood cancer.”**

---

The aims of DKMS UK are to:

- Raise awareness of blood stem cell donation;
- Increase the number and diversity of registered potential blood stem cell donors in the UK; and
- Provide more second chances at life for those with blood cancer or blood disorders whose survival depends upon being matched with an unrelated blood stem cell donor.

## Public benefit

DKMS UK raises awareness of blood cancers and blood disorders in the UK, including the life-changing impact of a diagnosis, in order that increasing numbers of the general public know about the need for more people to register as a potential blood stem cell donor. Increasing the number and diversity of potential blood stem cell donors is vital in increasing the life chances of blood cancer and disorder patients who need a blood stem cell transplant. At present, only 7% of the UK's eligible population are registered as donors compared to much higher levels in some other countries.

Registering more potential blood stem cell donors means that we are able to provide more second chances at life by finding and supporting an unrelated blood stem cell donor who can and will donate their stem cells for a patient in need of a life-saving blood stem cell transplant.

Through recruiting, registering and supporting blood stem cell donors to be part of life-saving treatments, we deliver significant public benefit to patients and their families and to the National Health Service, which arranges treatment and care for those patients.

The Trustees review the aims, objectives and activities of DKMS UK each year, ensuring the Charity remains focused on its stated purpose. This report looks at what DKMS UK has achieved and the outcomes of its work in the reporting period.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

## Board and management operations

The Board of Trustees meets twice a year to review DKMS UK's work, finances and services, and to agree the strategic goals for the Charity.

## Recruitment and appointment of new Trustees

Trustees are appointed on the basis of their relevant skills and experience. The ongoing Trustees are responsible for the induction of any new Trustees, which involves an awareness of a Trustee's responsibilities, the governing document, administrative procedures, the history, approach and current business plan of DKMS UK.

The Trustees also make available a welcome pack to include copies of the previous year's annual report and financial statements, a brief history of the charitable company and a copy of the governing document. The pack also includes a copy of the Charity Commission guidance 'The essential Trustee: What you need to know. What you need to do.'

While DKMS UK is connected through common Trustees to DKMS Group gGmbH ('DKMS'), it continues to aim to recruit additional Trustees that can broaden and support its representation in the UK.

## Management and organisation

Day-to-day operations of the Charity and strategy implementation is delegated to the Country Managers supported by the Senior Leadership Team (SLT). In the absence of the Country Managers, Stephan Schumacher, Trustee oversees the work of the SLT.

The Senior Leadership Team comprises:

- Country Managers Hasnein Alidina and Peter McCleave.
- Head of Communications and Engagement Daniel Philipp Hoffmann.
- Head of Finance Margaret Brett.
- Head of Fundraising Caroline Richardson.
- Head of Donor Support Services Josh Winters.
- HR Manager Lisa Karlsson.
- Head of Donor Recruitment Hannah Tarrant.
- Donor Request Management Work Up Team Lead Louise Bailey.
- Donor Request Management Confirmatory Typing Team Lead Lindsey Dean.

## Related parties

The only related parties are considered to be the Trustees and those connected with the Trustees, including their close family, business and other charity interests. There have been no transactions with related parties, nil reimbursement to Trustees.



# DKMS Foundation: Trustee Report

## Remuneration

In order to recruit and retain staff of the calibre it requires, DKMS UK's pay policy is to remunerate staff at levels above the voluntary sector median rate, but below the private sector market rate.

The Charity has an organisational salary structure based upon a job evaluation study and external salary benchmarking concluded in June 2023.

New roles are assessed against the job evaluation criteria and placed in a corresponding grade in the structure.

The salary structure's pay levels are reviewed at least annually by the Country Managers to ensure that salary scales are aligned with those for similar positions in the external market. A review of salaries normally takes place annually, and is usually implemented in January. If changes are to be made, staff are advised in writing of the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health and achievements.

With reference to the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration), the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the Charity's remuneration policy and approach to senior executive pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to 'key management personnel' (which we have defined as the Senior Leadership Team), in line with the accounting Statement of Recommended Practice 2019 for charities. Given the Charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual/personal salary of any individual member of staff including senior executives, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements).

## Our approach to fundraising

We continue to uphold the highest standards in how we communicate with our fundraising donors and supporters and ensure that our fundraising practices meet the requirements of the recommended Codes of Practice.

We treat our donors and supporters with great respect and gratitude that befits a community of people and organisations that make our work possible.

### Key aspects of our approach to fundraising include:

Registration with the Fundraising Regulator, which maintains the standards for charitable fundraising and ensures that fundraising is respectful, open, honest and accountable to the public. It also takes complaints about fundraising, investigates cases and adjudicates on fundraising practice.

Ensuring our fundraising approach is aligned with the Charity's governing objectives.

We have a complaints policy, which outlines our commitment to resolving fundraising complaints as promptly and amicably as possible. It also sets out our process for handling any complaints received. As per our policy, complaints will be reported and referred to the Fundraising Regulator if a resolution with the complainant cannot be reached or if the complaint is about a breach of any aspect of the Code of Fundraising Practice.

In 2024 we did not receive any complaints across the organisation. Trustees are updated on a bi-annual basis with regards to the number of complaints we have handled in the year.

We raise funds through individual giving requests (cash appeals, regular donation asks and online giving), community, challenge events, corporate and trust fundraising.

We do not carry out any telephone, face-to-face or door-to-door fundraising.

We do not use third party agencies to make fundraising requests, although we do use them for fulfilment purposes, e.g. acquisition of charity place challenge events, processing direct debits or distribution of fundraising direct mail. In such situations, legal agreements are in place. In no other circumstance do we swap or share data and we never sell data.

All fundraising activity complies with the UK General Data Protection Regulation (GDPR) and associated legislation and guidance.

Promotional goods sent out for fundraising purposes, and use of our logo on external fundraising materials, is subject to approval. Official stationery, such as our letterhead, is never sent out for external use.

## **Risk assessment and management**

DKMS UK operates a risk assessment and management framework that reviews major risk areas on a quarterly basis.

The Country Managers and individual members of the SLT take responsibility for the day-to-day management and oversight of the above risk areas. The Trustees review the assessments and mitigating actions at their Board meetings and consider the following areas to be the major risks related to DKMS UK's operations and activities.

## **Medical safety of donors during the blood stem cell collection process**

Although the medical process and procedure for blood stem cell donation and collection is safe, well-established and regulated, there will always be some safety risks and DKMS UK acknowledges these and takes them seriously.

The risks to the safety of our donors before, during and after the donation process, as well as any risks to transplant patients from the collection of poor-quality stem cell product are managed and mitigated in the following ways:

- Working in line with approved and regularly reviewed Standard Operating Procedures that comply with domestic and international standards and regulations, and that include clear identification and reporting mechanisms for Serious Adverse Events and Reactions and Quality Incidents.
- Working only with experienced, trusted and appropriately regulated medical partners and services. These relationships in turn are governed via established legal contracts and service protocols and regular service reviews.
- Ensuring a thorough quality assurance system is in place within the organisation, including compliance with the World Marrow Donor Association (WMDA) standards (qualification for which was achieved and approved in March 2021).
- Ensuring ongoing training, support and continuing professional development for all staff involved in the blood stem cell registration and donation process.

# DKMS Foundation: Trustee Report

## Data management and protection

The collection, processing, storage and security of our blood stem cell donors' personal data and genetic information is of paramount importance and so represents a major risk in the event of mismanagement, loss or misuse of that data.

The potential damage to individual donors through a data breach, let alone the damage to DKMS UK's and the DKMS Group's reputation and activities in working with patients, donors, supporters and stakeholders would be catastrophic.

We manage and mitigate these risks through:

- Adherence to and compliance with strong information security and data protection policies and practices throughout the whole DKMS Group.
- Ensuring data processing and third parties and protocols are in place with suppliers and partners.
- Regular training and reviews for staff, volunteers and donor registration partners.
- Blood stem cell donor recruitment.

Effective and high-quality blood stem cell donor recruitment is essential to ensuring we meet the needs of patients and transplant centres looking for a match. If we fail to ensure we recruit sufficient numbers of donors with a diverse range of backgrounds, and also with accurate and regularly updated personal health and genetic information and contact details, then we risk not being able to save the lives of more blood cancer and blood disorder patients.

We manage and mitigate this risk by ensuring we have:

- Clear and compelling communications and explanations about the registration process and the need for blood stem cell donors.
- Effective quality check and review processes.
- Quality programmes to enhance the health and contact information we have on the priority groups among our blood stem cell donors.
- A system for prioritisation for recruiting, retaining and supporting potential and actual blood stem cell donors.

## Financial risks

There are a number of areas of financial risk faced by DKMS UK:

- Failure to achieve budgeted income levels.
- Inadequate financial controls or fraud.
- Poor financial management, including credit risk management, pricing risk and foreign exchange and liquidity risks.

These risks are managed and mitigated in the following ways:

- Strong planning, budgeting and monitoring processes in relation to income streams, including fundraising.
- Strong internal financial controls and data security.
- Regular reviews of fraud risks.
- Close interaction, support and cross-checking with the international financial management and controlling teams in Germany.
- Vetting by DKMS Germany of international health services, registries and companies involved in stem cell transplantation, so that stringent assessments on credit risk are carried out and appropriate financial terms agreed for all DKMS companies within the Group.
- Ensuring pricing of products and services is set at reasonable and affordable levels, that recognise the Group's role as a healthcare service provider with a primary objective of saving lives. Pricing levels are based on a production cost structure and also acknowledge differences in international economies, as well as the need to ensure patient treatments are not jeopardised by costs.



- Maintaining good cash flow and financial management systems in order to manage fluctuations in the major trading currencies in which DKMS UK deals.
- Cash flow projections are prepared as part of the Charity's strategic planning, while liquidity levels are monitored internally on a daily basis as well as reported to central management and Trustees at each reporting period.
- Adequate balances are maintained in all currencies to ensure sufficient funding is available to meet commitments.

### **Logistical and supply line business continuity and resilience**

Ensuring we have reliable, efficient and cost-effective methods for transporting our swab packs, blood samples and collected blood stem cells is crucial to the successful achievement of our organisational goals and objectives to save more lives, as is having a well-stocked and maintained supply line, resources and medicines. To manage and mitigate the risks of business-critical supplies and logistical arrangements we have:

- Implemented strong review processes for stock control and order processing.
- Made alternative arrangements and contingency plans for business continuity and disaster recovery scenarios.
- Developed contingency plans to provide for business periods where we are working at higher than normal levels of activity or volume (e.g. when running successful campaigns).

### **UK's economic challenges and its effects on DKMS UK business activities**

The UK economy in common with almost all countries in the world experienced a sharp increase in the cost of living with inflation reaching over 11% for a short period in late 2022. The Bank of England and the UK government implemented various economic policies to prevent the inflation rate imbedding in the economy and spiralling out of control. Fall in energy prices and good economic governance has resulted in reducing UK's inflation rate to about 2.5% by mid-2024. The UK economic outlook now appears more positive and predictable. However significant part of the cost increases cannot be passed on and are therefore absorbed by the charity. The UK inflation rate remains at 3.8%.

### **Financial review**

#### **Going concern**

The Board of Trustees of the ultimate parent company approved an arrangement to continue funding DKMS UK's main activities to meet all its liabilities from its principal, DKMS Group gGmbH for a period not less than 12 months from the date these financial statements are approved. Accordingly, the Trustees continue to adopt a going concern basis in preparing the financial statements.

The company's business activities in 2024 show positive results to budget and the trend is expected to continue for rest of the year with the company's funding requirements expected to remain well within the amounts approved by the board for next three years.

The charitable company's net current assets at 31 December 2024 were 2,410,827 (2023: £2,665,040). Further details regarding the adoption of the going concern basis can also be found in the Accounting Policies on page 30.

# DKMS Foundation: Trustee Report

## Financial results

DKMS UK received donations totalling £4,817,209 (2023: £3,597,777) of which £3,025,173, (2023: £2,559,143) was donated funds, £1,792,036 (2023: £1,038,634) was donated services from DKMS in Germany.

The charity company's net expenditure for the year amounted to £28,759 (2023: net income £459,791) The reduction in net income was influenced by absorption of higher costs for its charitable activities and costs of supporting and growing DKMS brand awareness in India. This is to encourage donor awareness and registration for treatment of blood cancer, Thalassemia and other blood disorders.

## Reserves policy

DKMS UK's aim is to gradually grow its unrestricted funds and achieve full financial independence. While the Charity is growing its income base and cash flow, it continues to receive funding for its main activities from its principal, DKMS Group gGmbH. The Trustees have approved for this arrangement to continue for the foreseeable future and until DKMS UK becomes financially independent to meet all its liabilities for at least 12 months. As at 31 December 2024 DKMS UK's unrestricted funds were £2,659,153 (2023: £2,687,912).

## Principal funding

In the period under review, DKMS UK's significant funding comes from donations from DKMS Group in Germany. In the meantime, the charitable company continues to grow its fee income from referral of potential blood stem cell donors and management of peripheral blood stem cell or bone marrow collections and establishing a broader base of additional funding sources to grow its voluntary donation income.

The charity has also developed a fundraising strategy to raise additional funding through new voluntary donations initiatives and events.

## Future developments

DKMS remains focussed on achieving steady growth in number of stem cell donations.

We are aware that our donation volume may show some reduction over next 2-3 years as we refocus on increasing our donor pool of young and preferred aged donor group.

Recruitment must remain targeted, with a particular focus on young donors and from ethnic minority communities, as those groups will further help increase our overall number of matched donors, and move us closer to levelling up access to transplantation in these communities.

Fundraising work is planned to grow significantly over the next three years to support our expansion, with important areas for future growth being community-based and volunteer-led programmes, along with an expanded corporate support programme. This support is vital to achieve our aim of finding a matching donor for every stem cell transplant patient that needs one and where required covering the costs of the transplant.

## Change of trustees and directors

Dr A H Schmidt resigned as Trustee on 22nd January 2025.

## Trustees' responsibilities statement

The Trustees (who are also directors of DKMS Foundation for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.

In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- Make judgments and accounting estimates that are reasonable and prudent;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

## Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- So far as that Trustee is aware, there is no relevant audit information of which the charitable company's auditors are unaware, and
- That Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information.

This report was approved by the Trustees and signed on their behalf by:



**Bernd Weinel**  
Trustee

Date: 7th November 2025



# *DKMS Foundation:* **Independent auditors’ report to the members and trustees**

## **Opinion**

We have audited the financial statements of DKMS Foundation (the ‘charity’) for the year ended 31 December 2024 which comprise the Statement of Financial Activities, Balance Sheet, Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- Give a true and fair view of the state of the charity’s affairs as at 31 December 2024 and of income and expenditure for the year then ended;
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

## **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the “Auditor’s responsibilities for the audit of the financial statements” section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

## Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

## Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the trustees' report which includes the directors' report prepared for the purposes of company law for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- The directors' report included within the trustees' report has been prepared in accordance with applicable legal requirements.

## Matters on which we are required to report by exception

In light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- Adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- The financial statements are not in agreement with the accounting records and returns; or
- Certain disclosures of trustees' remuneration specified by law are not made; or
- We have not received all the information and explanations we require for our audit.
- The trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption in preparing the trustees' report and from the requirement to prepare a strategic report.

# *DKMS Foundation:* **Independent auditors’ report to the members and trustees**

## **Responsibilities of Trustees**

As explained more fully in the trustees’ responsibilities statement set out on page 22, the trustees (who are also directors of the charity for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

## **Auditors’ responsibilities for the audit of the financial statements**

We have been appointed as auditor under Section 44(1)(C) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

Based on our understanding of the charity and its sector, we considered that non-compliance with the following laws and regulations might have a material effect on the financial statements: employment regulation, health and safety regulation, anti-money laundering regulation.

To help us identify instances of non-compliance with these laws and regulations, and in identifying and assessing the risks of material misstatement in respect to non-compliance, our procedures included, but were not limited to:

- Inquiring of management and, where appropriate, those charged with governance, as to whether the charity is in compliance with laws and regulations, and discussing their policies and procedures regarding compliance with laws and regulations;
- Inspecting correspondence, if any, with relevant licensing or regulatory authorities;
- Communicating identified laws and regulations to the engagement team and remaining alert to any indications of non-compliance throughout our audit; and
- Considering the risk of acts by the charity which were contrary to applicable laws and regulations, including fraud.



We also considered those laws and regulations that have a direct effect on the preparation of the financial statements, such as tax legislation, pension legislation, the Charities Act 2011 and the Companies Act 2006.

In addition, we evaluated the trustees' and management's incentives and opportunities for fraudulent manipulation of the financial statements, including the risk of management override of controls, and determined that the principal risks related to posting manual journal entries to manipulate financial performance, management bias through judgements and assumptions in significant accounting estimates, in particular in relation to accruals, income recognition (which we pinpointed to the cut-off assertion) and significant one-off or unusual transactions.

Our audit procedures in relation to fraud included but were not limited to:

- Making enquiries of the trustees and management on whether they had knowledge of any actual, suspected or alleged fraud;
- Gaining an understanding of the internal controls established to mitigate risks related to fraud;
- Discussing amongst the engagement team the risks of fraud; and
- Addressing the risks of fraud through management override of controls by performing journal entry testing.

## Use of the audit report

This report is made solely to the charity's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charity's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity, the charity's members as a body and the charity's trustees as a body for our audit work, for this report, or for the opinions we have formed.

**NJ Wakefield**

**Nicola Wakefield (Senior Statutory Auditor)  
for and on behalf of Forvis Mazars LLP.**

Chartered Accountants and Statutory Auditor,  
6 Sutton Plaza, Sutton Court Road, Sutton  
Surrey, SM1 4FS.

Date: 12th November 2025

# DKMS Foundation: Statement of financial activities

(Incorporating income and expenditure account)  
for the year ended 31 December 2024

		Unrestricted funds 2024	Total funds 2024	Total funds 2023
	Note	£	£	£
<b>Income from</b>				
Donations and legacies	2	4,817,209	4,817,209	3,597,777
Charitable activities	3	8,079,045	8,079,045	8,323,916
<b>Total Income</b>		<b>12,896,254</b>	<b>12,896,254</b>	11,921,693
<b>Expenditure on</b>				
Raising funds	4	1,317,842	1,317,842	1,275,335
Charitable activities	5, 6 and 9	12,571,825	12,571,825	10,186,570
	7, 19	13,889,667	13,889,667	11,461,905
<b>Net income / (expenditure) before prior year VAT adjustments other recognised gains and losses</b>		<b>-993,413</b>	<b>-993,413</b>	459,791
Net income relating to prior year VAT treatment change	12	964,654	964,654	-
<b>Net income / (expenditure) before other recognised gains and losses</b>		<b>-28,759</b>	<b>-28,759</b>	459,791
<b>Reconciliation of funds</b>				
Total funds brought forward		2,687,912	2,687,912	2,228,121
<b>Total funds carried forward</b>		<b>2,659,153</b>	<b>2,659,153</b>	2,687,912

All activities relate to continuing operations. The unrestricted funds above includes £227,554 of income (2023:£175,000) and £227,554 of expenditure (2023:£175,000) that is restricted to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

The notes on pages 30 to 49 form part of these financial statements.

# DKMS Foundation: Balance Sheet

As at 31 December 2024

		2024		2023	
	Note	£	£	£	£
<b>Fixed assets</b>					
Tangible assets	13		<b>248,324</b>		22,871
Investments	14		<b>1</b>		1
			<b>248,326</b>		22,872
<b>Current assets</b>					
Inventory	15	<b>60,688</b>		258,696	
Debtors	16	<b>2,924,811</b>		2,058,021	
Cash at bank and in hand	22	<b>887,731</b>		1,932,055	
		<b>3,873,230</b>		4,248,772	
<b>Creditors: amounts falling due within one year</b>	17	<b>(1,462,403)</b>		(1,583,732)	
Net current assets			<b>2,410,827</b>		2,665,040
Net assets			<b>2,659,153</b>		2,687,912
<b>Charity Funds</b>					
Unrestricted funds	19		<b>2,659,153</b>		2,687,912
<b>Total funds</b>	<b>20</b>		<b>2,659,153</b>		2,687,912

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. However, an audit is required in accordance with section 144 of the Charities Act 2011.

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the trustees.

*Bernd Weinel*

**Bernd Weinel**

Trustee

Date: 7th November 2025

The notes on pages 30 to 49 form part of these financial statements.



# DKMS Foundation: Statement of cash flows

For the year ended 31 December 2024

		2024	2023
	Note	£	£
<b>Cash flows from operating activities</b>			
Net cash provided by operating activities	21	<b>(765,684)</b>	191,963
<b>Cash flows from investing activities</b>			
Purchase of tangible fixed assets		<b>(278,640)</b>	(9,848)
<b>Net cash used in investing activities</b>		<b>(278,640)</b>	(9,848)
<b>Change in cash and cash equivalents in the year</b>		<b>(1,044,324)</b>	182,115
Cash and cash equivalents brought forward		<b>1,932,055</b>	1,749,940
<b>Cash and cash equivalents carried forward</b>	22	<b>887,731</b>	1,932,055

The notes on pages 30 to 49 form part of these financial statements.

# *DKMS Foundation:*

# **Notes to the financial statements for the year ended 31 December 2024**

## **01. Accounting Policies**

### **1.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

DKMS Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in pound sterling (£).

### **1.2 Going concern**

The trustees of the ultimate parent company review the company's activities and 3 year business plan each year and establish and approve funding level required to enable the company to achieve its goals and meet its business commitments and liabilities

The Trustees have approved arrangement to continue funding the charitable company's main activities from its principal, DKMS Gemeinnutzige GmbH until the company becomes financially independent to meet all its liabilities for a period not less than twelve months from the date these financial statements are approved. Accordingly, they continue to adopt going concern basis in preparing the financial statements.

### **1.3 Company status**

The charitable company is limited by guarantee. The members of the company are the trustees named on the back page. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

### **1.4 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 1.5 Income

All income is recognised once the charitable company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Money donation income is recognised when the income is credited into the company's account and revenue for clinical services is recognised after services are delivered.

Donated services or facilities are recognised when the charitable company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charitable company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). General volunteer time is not recognised. Further information about volunteer contribution is included in the trustees' report.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charitable company which is the amount the charitable company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

## 1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated to the applicable expenditure headings:

- Costs of generating funds comprise the costs associated with attracting voluntary income.

- Charitable expenditure comprises those costs incurred by the charitable company in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.
- Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charitable company and include the audit fees and costs linked to the strategic management of the charitable company.
- All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly; others are apportioned on an appropriate basis. Staff costs are allocated based on staff numbers, premises costs are allocated based on space occupied.

## 1.7 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of accumulated depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

- Leasehold improvements - over period of lease straight line.
- Office equipment - 33.33% per annum straight line.
- Computer equipment - 33.33% per annum straight line.



# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 1.8 Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value. Investments in subsidiary companies are stated at cost less diminution in value.

## 1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

## 1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

## 1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

## 1.12 Creditors and provisions

Creditors and provisions are recognised where the charitable company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

## 1.13 Pensions

The charitable company operates a defined contribution pension scheme and the pension charge represents the amount payable by the charitable company in respect of the year.

## 1.14 Financial instruments

The charitable company has applied Sections 11 and 12 of (FRS 102) in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charitable company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable company after deducting all of its liabilities.

The charitable company's policies for its major classes of financial assets and financial liabilities are set out below.

### Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances, related charity working capital balances, and related charity financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans and loans from related charities, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

## Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the charitable company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

## Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

## Critical accounting estimates and areas of judgment

Management does not consider there to be any key judgements or estimates made in the preparation of the financial statements.

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 02. Donations and legacies

	Unrestricted funds 2024	Total funds 2024	Total funds 2023
	£	£	£
Donation income	<b>1,963,061</b>	<b>1,963,061</b>	1,906,353
International donation income	<b>1,062,112</b>	<b>1,062,112</b>	652,790
Funding for donor recruitment activities from DKMS Gemeinnutzige GmbH	<b>1,792,036</b>	<b>1,792,036</b>	1,038,634
Other income	-	-	-
Total donations and legacies	<b>4,817,209</b>	<b>4,817,209</b>	3,597,777
<b>Total 2023</b>	<b>3,597,777</b>	<b>3,597,777</b>	

Donation income includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

## 03. Charitable activities

	Unrestricted funds 2024	Total funds 2024	Total funds 2023
	£	£	£
Income from service provision	<b>8,079,045</b>	<b>8,079,045</b>	8,323,916
<b>Total 2023</b>	<b>8,323,916</b>	<b>8,323,916</b>	

In the year ended 31 December 2024 and 2023 all income related to unrestricted funds.



## DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

### 04. Raising funds

	Unrestricted funds 2024	Total funds 2024	Total funds 2023
	£	£	£
Salaries, national insurance and pensions	<b>433,322</b>	<b>433,322</b>	398,184
Other staff costs and training	<b>22,689</b>	<b>22,689</b>	29,990
Premises costs	<b>65,546</b>	<b>65,546</b>	43,195
Publicity & Awareness costs	<b>586,347</b>	<b>586,347</b>	600,138
Postage, support and stationery	<b>3,396</b>	<b>3,396</b>	1,794
Other admin costs	<b>174,340</b>	<b>174,340</b>	170,539
Travel costs	<b>5,995</b>	<b>5,995</b>	6,367
Loss on foreign exchange	<b>18,495</b>	<b>18,495</b>	17,218
Depreciation	<b>7,712</b>	<b>7,712</b>	7,910
	<b><u>1,317,842</u></b>	<b><u>1,317,842</u></b>	<u>1,275,335</u>
<b>Total 2023</b>	<u>1,275,335</u>	<u>1,275,335</u>	

## DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

### 05. Direct costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2024	Total 2023
	£	£	£	£	£
Other direct costs	168,740	35,719	3,643,346	3,847,805	3,313,754
International donor projects - India - Africa	1,008,727	1,775,824	-	2,784,551	2,053,219
Other staff costs and training	628	394	(5,576)	(4,554)	11,506
Premises cost	70,954	116,416	125,186	312,557	194,271
Publicity cost	77,108	269,832	12,204	359,144	358,734
Loss on foreign exchange	17,432	17,432	41,401	76,266	58,255
Postage, support and stationery	199,843	121,919	143,204	464,966	331,409
Travel costs	32,317	5,822	19,841	57,981	28,322
Donor typing costs	1,062,112	-	-	1,062,112	1,038,634
Salaries, national insurance and pensions	375,377	363,960	874,526	1,613,862	1,341,748
Depreciation	7,269	7,269	17,263	31,801	26,762
	<b>3,020,508</b>	<b>2,714,587</b>	<b>4,871,396</b>	<b>10,606,491</b>	<b>8,756,614</b>
<b>Total 2023</b>	<u>2,121,295</u>	<u>2,364,863</u>	<u>4,270,456</u>	<u>8,756,614</u>	

Direct costs includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 06. Support costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2024	Total 2023
	£	£	£	£	£
Legal and professional fees	23,507	40,268	39,855	103,631	160,697
Loss on foreign exchange	7,228	7,228	17,166	31,621	24,965
Other staff costs and training	29,039	29,039	68,968	127,047	144,394
Premises costs	24,100	41,283	40,859	106,241	69,379
Travel costs	2,657	2,657	6,311	11,626	24,834
Other support costs	110,121	110,121	308,300	528,541	142,938
Postage, support and stationery	560	560	1,331	2,450	1,122
Admin costs	(1,576)	(1,576)	(3,742)	(6,893)	1,243
Salaries, national insurance and pensions	228,288	228,288	542,184	998,760	783,979
Depreciation	3,014	3,014	7,158	13,186	11,470
<b>Total 2024</b>	<b>426,938</b>	<b>460,882</b>	<b>1,028,391</b>	<b>1,916,210</b>	<b>1,365,021</b>
<b>Total 2023</b>	<b>287,006</b>	<b>324,217</b>	<b>753,798</b>	<b>1,365,021</b>	

In the year ended 31 December 2024 and 2023 all expenditure related to unrestricted funds.



# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 07. Analysis of expenditure by expenditure type

	Staff Costs 2024	Depreciation 2024	Other Costs 2024	Total 2024	Total 2023
	£	£	£	£	£
Expenditure on raising voluntary income	<b>433,322</b>	<b>7,712</b>	<b>876,808</b>	<b>1,317,842</b>	1,275,335
Costs of raising funds	<b>433,322</b>	<b>7,712</b>	<b>876,808</b>	<b>1,317,842</b>	1,275,335
Recruitment of donors	<b>603,665</b>	<b>10,283</b>	<b>2,833,499</b>	<b>3,447,446</b>	2,408,299
Raising awareness	<b>592,248</b>	<b>10,283</b>	<b>2,572,940</b>	<b>3,175,470</b>	2,689,081
Donor request management	<b>1,416,710</b>	<b>24,422</b>	<b>4,458,654</b>	<b>5,899,786</b>	5,024,255
Charitable activities	<b>2,612,622</b>	<b>44,987</b>	<b>9,865,093</b>	<b>12,522,702</b>	10,121,635
Expenditure on governance	<b>0</b>	<b>0</b>	<b>49,124</b>	<b>49,124</b>	64,932
<b>Total 2024</b>	<b>3,045,944</b>	<b>52,699</b>	<b>10,791,024</b>	<b>13,889,668</b>	11,461,902
<b>Total 2023</b>	<b>2,523,912</b>	<b>46,142</b>	<b>8,891,848</b>	<b>11,461,902</b>	

Direct costs includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

Expenditure on raising voluntary income has not been allocated to specific activities as all costs relate to general charitable activities.

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 08. Analysis of expenditure by activities

	Activities undertaken directly 2024	Support costs 2024	Total 2024	Total 2023
	£	£	£	£
Recruitment of donors	3,020,508	426,938	3,447,446	2,408,301
Raising awareness	2,714,587	460,882	3,175,469	2,689,080
Donor request management	4,871,396	1,028,391	5,899,786	5,024,254
<b>Total 2024</b>	<b>10,606,491</b>	<b>1,916,211</b>	<b>12,522,702</b>	10,121,635
<b>Total 2023</b>	8,756,614	1,365,021	10,121,635	

Direct costs includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

## 09. Governance costs

	Unrestricted funds 2024	Total funds 2024	Total funds 2023
	£	£	£
Auditors' remuneration	25,750	25,750	29,400
Legal and professional fees	23,374	23,374	35,532
<b>Total</b>	<b>49,124</b>	<b>49,124</b>	64,932

In the year ended 31 December 2024 and 2023 all costs of direct charitable activities related to unrestricted funds.

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 10. Net resources expended

This is stated after charging:

	2024	2023
	£	£
<b>Depreciation of tangible fixed assets</b>		
- Owned by the charity	52,699	46,142
Auditors' remuneration - audit	25,750	29,400
- Non-audit services Taxation advice	31,100	26,710

During the year, no trustees received any remuneration (2023- £Nil).

During the year, no trustees received any benefits in kind (2023 - £Nil).

During the year, no trustees received any reimbursement of expenses (2023 - £Nil).

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 11. Staff Costs

Staff costs were as follows:

	2024	2023
	£	£
Salaries	2,645,831	2,197,776
Social security costs	263,127	218,697
Pension costs	103,519	80,823
<b>Total</b>	<b>3,012,477</b>	<b>2,497,296</b>

The average monthly number of employees was: 58 (2023: 50) and the average monthly number of employees during the year expressed as follows

Full time equivalents was as follows (including part-time and fixed period temporary staff):

	2024	2023
	No.	No.
Donor recruitment	8	6
Fundraising	6	6
Communications	8	6
Medical	19	17
Administration	8	8
Donor Service	6	6
Charity activity development	3	1
<b>Total</b>	<b>58</b>	<b>50</b>



# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

The number of higher paid employees was:

	2024	2023
	No.	No.
In the band £60,001 - £70,000	4	4
In the band £70,001 - £80,000	3	1
In the band £80,001 - £90,000	0	0
In the band £90,001 - £100,000	0	0
In the band £100,001 - £110,000	1	0
In the band £110,001 - £120,000	0	1
In the band £120,001 - £130,000	0	0
In the band £130,001 - £140,000	0	0
In the band £140,001 - £150,000	1	0
In the band £150,001 - £160,000	0	0
<b>Total</b>	<b>9</b>	<b>6</b>

The charitable company trustees were not paid or received any other benefits from employment with the charitable company in the year (2023: £Nil) neither were they reimbursed expenses during the year (2023: £Nil). No charitable company trustee received payment for professional or other services supplied to the charitable company (2023: £Nil)

The key management personnel of the charitable company are the trustees, the Chief Executive Officer,the heads of departments and team leads. There are 11 heads of department and team leads (2023: 6), nine of whom received remuneration in excess of £60,000 during the year (2023: 6). The total employee benefits of the key management personnel of the charitable company were £927,942 (2023: £626,365).

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 12. Net income relating to prior year VAT treatment change

The adjustment relates to net VAT charge following change in the charity's VAT status from a change in Stem cell collection process in 2020. Input VAT of £656,984 is now payable and output VAT of £1,621,638 is now claimable for periods from July 2020 - December 2023

## 13. Tangible assets

	Office Equipment	Computer Equipment	Leasehold Improvements	Total
Cost	£	£	£	£
At 1 January 2024	69,800	176,721	228,855	475,376
Additions	123,952	29,414	125,274	278,640
Disposals	(80,973)	(22,176)	(104,369)	(207,518)
At 31 December 2024	112,779	183,959	249,760	546,498
<b>Accumulated Depreciation</b>				
At 1 January 2024	65,887	157,763	228,855	452,505
Charge for the year	18,623	18,402	15,673	52,698
Release on disposal	(80,973)	(21,688)	(104,369)	(207,030)
At 31 December 2024	3,537	154,477	140,159	298,173
<b>Net book value</b>				
At 31 December 2024	109,242	29,482	109,601	248,325
At 31 December 2023	3,913	18,958	-	22,871

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 14. Investments

	Shares in Group Undertakings
	£
<b>Costs and net book value</b>	
At 31 December 2024 and 31 December 2023	1

The company's wholly owned subsidiary, Delete Blood Cancer UK Marketing Limited, registered at Ashburnham House, Castle Row, Horticultural Place, London W4 4JQ is a dormant company. Its net liability position at 31 December 2024. £10,245 (2023: £10,245) is represented by amounts due to parent company and is fully provided for in the accounts of the parent company.

## 15. Inventory

Inventory costs were as follows:

	2024	2023
	£	£
Materials stock	50,999	153,757
Work in progress costs	9,689	104,939
<b>Total</b>	<b>60,688</b>	<b>258,696</b>

Inventories are valued at lower of cost and net realisable value. Work in progress costs are reimbursable costs incurred for active stem cell collections awaiting to be billed.

## 16. Debtors

	2024	2023
	£	£
<b>Due within one year</b>		
Trade debtors	1,949,139	1,505,825
Amounts owed by group undertakings	10,245	10,245
Amounts owed by related charity	217,495	332,338
Other debtors	495,757	8,092
Prepayments and accrued income	252,175	201,521
<b>Total</b>	<b>2,924,811</b>	<b>2,058,021</b>

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 17. Creditors: Amounts falling due within one year

	2024	2023
	£	£
Trade creditors	431,061	459,989
Amounts owed to related charity	6,929	10,336
Other creditors	109,038	184,490
Deferred revenue - UK Gala	223,519	270,000
Other taxation and social security	80,899	67,473
Accruals	610,957	591,444
<b>Total</b>	<b>1,462,403</b>	<b>1,583,732</b>

Other creditors include £223,519 (2023: £270,000) deposits received for the fundraising event scheduled to be held in May 2025.

## 18. Financial instruments

	2024	2023
	£	£
<b>Financial assets</b>		
Financial assets that are debt instruments measured at amortised cost	2,672,636	1,856,500
<b>Financial liabilities</b>		
Financial liabilities measured at amortised cost	(437,990)	(470,325)
<b>Total</b>	<b>2,234,646</b>	<b>1,386,175</b>

Financial assets measured at amortised cost include trade debtors, amounts owed by group companies, other debtors and amounts owed by related charity

Financial liabilities include trade creditors and amounts owed to a related charity.



# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 19. Summary of funds

	2024	2023
	£	£
At 1 January	2,687,912	2,228,121
Income for year	12,896,254	11,921,693
Resource expended	(13,889,667)	(11,461,902)
Net income relating to prior year VAT treatment change	964,654	-
<b>At 31 December</b>	<b>2,659,153</b>	<b>2,687,912</b>

## 20. Analysis of net assets between funds

Analysis of net assets between funds - current year:

	Unrestricted funds 2024	Total funds 2024
	£	£
Tangible fixed assets	248,325	248,325
Fixed asset investments	1	1
Current assets	3,873,230	3,873,230
Creditors due within one year	(1,462,403)	(1,462,403)
<b>Total</b>	<b>2,659,153</b>	<b>2,659,153</b>

Analysis of net assets between funds - prior year:

	Unrestricted funds 2023	Total funds 2023
	£	£
Tangible fixed assets	22,871	22,871
Fixed asset investments	1	1
Current assets	4,248,772	4,248,772
Creditors due within one year	(1,583,732)	(1,583,732)
<b>Total</b>	<b>2,687,912</b>	<b>2,687,912</b>

## DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

### 21. Reconciliation of net movement in funds to net cash flow from operating activities

	2024	2023
	£	£
Net income for the year (as per Statement of Financial activities)	(28,759)	459,791
<b>Adjustment for</b>		
Depreciation charges	52,698	46,142
Loss on disposal	488	-
(Increase) in debtors	(866,790)	(744,872)
Increase / (Decrease) in creditors	(121,329)	404,583
Decrease in inventory	198,008	26,319
<b>Total</b>	<b>(765,684)</b>	<b>191,963</b>

### 22. Analysis of cash and cash equivalents

	2024	2023
	£	£
Cash at bank and in hand	887,731	1,932,055
<b>Total</b>	<b>887,731</b>	<b>1,932,055</b>

### 23. Operating lease commitments

At 31 December 2024 the total of the charity's future minimum lease payments under non-cancellable operating leases was:

	2024	2023
	£	£
Within 1 year	266,951	266,951
Between 2 and 5 years	740,150	1,007,101
Over 5 years	-	-
<b>Total</b>	<b>1,007,101</b>	<b>1,274,052</b>

Lease payments recognised as an expense amounted to **£270,705** (2023: £255,910).

# DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

## 24. Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 "Related Party Disclosures" from disclosing transactions with entities which are a wholly owned part of the group.

Transactions with other related parties are as follows:

Name (relationship)	Transaction	Amount		Amount due from / (to) related party	
		2024	2023	2024	2023
		£	£	£	£
DKMS Donor Centre gGmbH (Common Trustees)	Donated services	<b>6,250</b>	-	<b>(395)</b>	-
DKMS Donor Centre gGmbH (Common Trustees)	Intercompany funding	-	560,484	-	319,810
DKMS Group gGmbH (Common Trustees)	Donated services	<b>1,062,112</b>	1,038,634	-	-
DKMS Group gGmbH (Common Trustees)	ATT	<b>230,000</b>	-	-	-
DKMS Group gGmbH (Common Trustees)	Intercompany recharges	<b>477,048</b>	302,352	-	(12,994)
DKMS Group gGmbH (Common Trustees)	Interco funding	<b>1,792,036</b>	-	<b>186,351</b>	-
DKMS Registry Gemeinnutzige GmbH	Intercompany service provision	<b>102,058</b>	101,610	<b>(5,665)</b>	(3,780)
DKMS USA (Common Trustees)	Intercompany service provision and recharges	<b>29,747</b>	10,341	<b>(839)</b>	(942)
DKMS USA (Common Trustees)	International money donation	<b>50,519</b>	7,857	-	-
DKMS ASIA (India)	Intercompany support services	<b>1,650,873</b>	-	-	-
DKMS BMST (India)	Intercompany support services	<b>1,011,916</b>	2,142,741	-	-
DKMS Foundation NPC (South Africa)	Intercompany service provision	<b>35,879</b>	50,635	<b>14,696</b>	12,703
Fundacja DKMS (Poland)	Intercompany Recharges	<b>1,695</b>	-	<b>1,695</b>	-

# **DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024**

Amounts owed to related parties are unsecured, interest free and due for repayment within one year.

DKMS Group gGmbH is the Controlling company and exercises full control over the charitable company through its common Trustees who are also directors of the company. The controlling company recharges the charitable company actual or appropriately apportioned costs it incurs in providing support to the latter.

The controlling company DKMS Group gGmbH entered into a contract with DKMS Life Science Lab whereby DKMS Foundation receives typing services for no consideration from 01 January 2021.

DKMS Life Science Lab is one of the leading HLA laboratories and provides this service for all DKMS entities.

## **25. Post balance sheet events**


No post balance sheet events.

## **26. Controlling party**

The trustees are the immediate controlling party and DKMS Group gGmbH is the ultimate controlling party. The principal address of the ultimate parent is Kressbach 1, 72072 Tübingen, Germany.

Copies of the group financial statements are available at [www.dkms.de](http://www.dkms.de).







# Ways you can support us

## Organise a donor registration event

Organise an event to encourage your friends, family or colleagues to register as potential stem cell donors.

## Create a bespoke partnership

DKMS can provide your company with networking and marketing opportunities aligned with our purposes and shared values.

## Payroll giving

Donate to DKMS through your company's Payroll Giving Scheme if employees are paid through PAYE.

## The 2K Club

Join our club of corporate supporters whose contribution goes towards helping the more than 2,000 people in the UK searching for a matching stem cell donor each year.

## Sponsored activities

From local 10k runs and marathons to multi-day cycle trips, challenge yourself and get fit!

## Fundraising events

Whether holding a bake sale, organising a music night or giving up a vice, every penny you raise helps in the fight against blood cancer.

## Daredevil challenges

If you fancy standing on top of a plane, jumping out of one, or filling your run with obstacles, we have something for everyone.

## Giving in memory

Many people choose to remember a loved one by fundraising for DKMS. We'll help you through the process to make sure their memory lives on through our work.















## A huge *thank you*

We would like to say a huge thanks to all Charitable Trust funders and Foundations who gave us their generous and ongoing support especially:

PF Charitable

C.A. Rookes Charitable Trust

B-CH 1971 Charitable Trust

Beaverbrook Charitable Trust

Gallagher Insurance  
Neighbourly Fund

Hudson Charitable Trust

Old Epsomian Lodge

The Artemis Charitable Foundation

The Clemens Neumann Nathan  
Charitable Trust

The Mistra Trust

## Trustees

Dr. E Neujahr  
B J Abel  
Bernd Weinel  
Dr. A H Schmidt (resigned 22nd January 2025)  
S Schumacher

## Principal staff

Hasnein Alidina, Country Manager,  
Finance and Operations

Peter McCleave, Country Manager,  
Communications and Engagement

## Registered company number

08151279

## Charity registered number

1150056 (England & Wales)

SC046917 (Scotland)

## Registered office

Ashburnham House, Castle Row,  
Horticultural Place  
London W4 4JQ

## Company secretary

B J Abel

## Independent auditors

Forvis Mazars LLP  
6 Sutton Plaza  
Sutton Court Road  
Sutton  
Surrey  
SM1 4FS

## Bankers

Barclays Bank plc  
74 Shepherds Bush Green  
Shepherds Bush  
London W12 8QD

Commerzbank AG  
30 Gresham Street  
London EC2V 7PG

110,000

**Transplants for people in need**

12m

**Potential donors registered**

24

**Lifesaving stem cell donations each day\***

\*Global DKMS statistics as of 31 December 2024

DKMS is the trading name of DKMS Foundation, a company limited by guarantee registered in England and Wales (08151279) and a charity registered in England and Wales (1150056) and Scotland (SC046917).